Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 10/20 | 1.00 |
| ▸ | HTR1A | P08908 | 7/20 | 0.45 |
| ▸ | DRD2 | P14416 | 7/20 | 0.45 |
| ▸ | HTR2A | P28223 | 7/20 | 0.45 |
| ▸ | DRD3 | P35462 | 7/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 3/20 | 0.42 |
| ▸ | DRD5 | P21918 | 3/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 3/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | CPT1A | P50416 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3289951 | 0.89 | CCR3 (0.79) | CCR3HTR1ADRD2HTR2ADRD3 | |
| SCHEMBL5742427 | 0.87 | CCR3 (0.76) | CCR3HTR1ADRD2HTR2ADRD3 | |
| SCHEMBL6017065 | 0.86 | CCR3 (0.75) | CCR3HTR1ADRD2HTR2ADRD3 | |
| SCHEMBL5383638 | 0.85 | CCR3 (0.74) | CCR3HTR1ADRD2HTR2ADRD3 | |
| SCHEMBL3293907 | 0.79 | CCR3 (0.65) | CCR3HTR1ADRD2HTR2ADRD3 | |
| SCHEMBL5393257 | 0.77 | CCR3 (0.65) | CCR3DRD2DRD3CPT1A | |
| SCHEMBL3289826 | 0.77 | CCR3 (0.62) | CCR3HTR1ADRD2HTR2ADRD3 | |
| Hydrochloric Acid SCHEMBL5382308 | 0.77 | CCR3 (0.64) | CCR3DRD2DRD3CPT1A | |
| SCHEMBL5393280 | 0.75 | CCR3 (1.00) | CCR3CPT1A | |
| SCHEMBL4003775 | 0.75 | CCR3 (0.59) | CCR3HTR1ADRD2HTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157471-B2 | Haloalkyl- and piperidine-substituted benzimidazole-derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-02 | — | — | US | disclosed |
| US-7157471-B2 | Haloalkyl- and piperidine-substituted benzimidazole-derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-02 | — | — | US | disclosed |
| US-7157471-B2 | Haloalkyl- and piperidine-substituted benzimidazole-derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-02 | — | — | US | disclosed |
| EP-1660476-B1 | HALOALKYL- AND PIPERIDINE-SUBSTITUTED BENZIMIDAZOLE-DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2006-12-27 | — | — | EP | disclosed |
| EP-1660476-A1 | HALOALKYL- AND PIPERIDINE-SUBSTITUTED BENZIMIDAZOLE-DERIVATIVES | Boehringer Ingelheim International GmbH (DE) | 2006-05-31 | — | — | EP | disclosed |
| US-20050124659-A1 | Haloalkyl- and piperidine-substituted benzimidazole-derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-06-09 | — | — | US | disclosed |
| WO-2005019203-A1 | HALOALKYL- AND PIPERIDINE-SUBSTITUTED BENZIMIDAZOLE-DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124659-A1 | Haloalkyl- and piperidine-substituted benzimidazole-derivatives | ABCB11, KCNJ11, CFTR | CCR3 1909/4885HTR1A 504/4885DRD2 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.